PCSK9 and coronary artery disorder: Administration of the PCSK9 inhibitor evolocumab to CHD patients, which up-regulates utilization of LDL in the liver, not only decreased the level of LDL cholesterol but also produced a comparative drop in the content of MDA-modified LDL.